Ultra-Long Acting Insulin Glargine

The aim of the project is to use innovative formulation technology to develop a proof-ofconcept
for insulin product with a consistent, ultra-long release profile. Formulations will first
be validated with the use of an in vitro model before demonstrating the ultra-long release
profile in a relevant animal model. Arecor is a biotherapeutic formulation company with a
technology that has the ability to elongate the time action profile of insulin whilst maintaining
a product stability profile suitable for commercialisation. The duration of action for currently
marketed products is less than 24 hours in at least a third of patients, which increases the risk
of severe life-threatening hypoglycaemic episodes. A consistent, elongated release profile will
offer reduced hypoglycaemic risk, whilst in turn improving dose flexibility resulting in
improved patient compliance, health benefits and savings for the healthcare provider.